Understanding and treating menstruation associated sickle cell pain

Area of Science:

• Hematology
• Gynecology
• Vascular Biology

Background:

• Sickle cell disease (SCD) is a chronic inflammatory condition causing vaso-occlusion and organ damage.
• Menstruation exacerbates SCD pain due to blood loss and inflammation.
• The interplay between SCD vascular stress and menstruation increases acute pain episodes.

Purpose of the Study:

• To explore the intersection of SCD and menstruation.
• To emphasize hormonal therapy's role in managing menstruation-associated acute SCD pain.

Main Methods:

• Review of existing data on hormonal therapies for SCD and menstruation.
• Analysis of progestin-only therapies (DMPA, LNG-IUDs) for menstrual blood loss.
• Evaluation of risks associated with combined hormonal contraceptives (CHCs) in SCD.

Main Results:

• Progestin-only therapies effectively reduce menstrual blood loss.
• Depot medroxyprogesterone acetate (DMPA) may mitigate acute SCD pain with low thrombotic risk.
• Combined hormonal contraceptives (CHCs) may increase hypercoagulable state risks in SCD patients.

Conclusions:

• Progestin-only hormonal therapies are beneficial for managing menstruation-associated pain in SCD.
• Careful consideration of thrombotic risks is crucial when selecting contraceptives for SCD patients.
• Collaboration between gynecologists and hematologists is vital for optimal patient care.